A recent study published in The Journal of Clinical Psychiatry suggests that a single dose of psilocybin, paired with psychological support, may rapidly and safely reduce chronic suicidal thoughts in adults with severe depression. The findings provide evidence that psychedelic-assisted therapy tends to offer lasting relief for individuals who have not responded to standard psychiatric treatments.
Chronic suicidal ideation presents a severe challenge in psychiatric care. It often persists even when patients undergo intensive trials of standard therapies or medications. Traditional interventions, such as standard antidepressant medications and cognitive behavioral therapy, tend to be effective for many individuals but typically require prolonged treatment periods. They may not provide immediate relief during acute phases of suicidal distress.
Other rapid-acting treatments, such as ketamine, offer promise for acute settings but present limitations regarding how long their effects last. Past research indicates that the anti-suicidal effects of these rapid treatments tend to fade within days or weeks. This creates a need for interventions that produce more enduring psychological and behavioral changes.
Psilocybin is the psychoactive compound found in “magic mushrooms.” It has gathered considerable attention for its potential to induce rapid and lasting psychological shifts when administered in a structured therapeutic environment. The substance acts by stimulating specific serotonin receptors in the brain, which temporarily alters brain network activity, particularly within the default mode network.
The default mode network is a collection of brain regions associated with self-reflection, mind-wandering, and rumination. In people with severe depression, this network tends to become overly rigid, locking individuals into repetitive negative thought patterns. Scientists propose that psilocybin disrupts this rigid activity, allowing the brain to relax deeply entrenched, maladaptive beliefs. This temporary flexibility might help people break free from the ruminative thinking that characterizes chronic suicidal ideation.
Despite these theoretical benefits, previous clinical trials evaluating psychedelics have almost entirely excluded participants with significant suicidal thoughts. Medical professionals usually view active suicidality as a severe safety risk that prohibits participation in experimental studies. Because of this cautious approach, previous trials evaluating psychedelics assessed suicidality only as a secondary safety measure rather than a primary target for treatment.
Scott T. Aaronson, chief science officer of the Institute for Advanced Diagnostics and Therapeutics at Sheppard Pratt and an adjunct professor of psychiatry at the University of Maryland, helped author the new study. He noted that the historical exclusion of this group created a noticeable gap in scientific knowledge.
“Patients with suicidal ideation are generally excluded from all depression trials,” Aaronson said. “Given the amount of attention psychedelics have had and the concern that there may be a signal for increased suicidality after psychedelic dosing, it seemed critical that we should look at this population and provide careful monitoring and support.”
To address this gap, the researchers organized an open-label trial involving twenty adults between the ages of eighteen and sixty-five. An open-label trial means that both the researchers and the participants knew what substance was being administered, and no placebo was used. The sample consisted of twelve men and eight women, with an average age of about thirty-six years. All participants had a confirmed diagnosis of major depressive disorder and experienced chronic suicidal thoughts.
These individuals also had a history of treatment resistance, meaning their symptoms persisted despite completing at least two adequate trials of standard antidepressant medications. Before the experimental session, participants completed a supervised process to slowly stop taking all their current psychiatric medications. The intervention itself involved a specialized synthetic formulation of psilocybin, alongside a structured psychological support program. This program included three preparatory therapy sessions designed to build trust and set intentions.
During the dosing session, participants received a single twenty-five-milligram oral dose of psilocybin in a dedicated room designed for physical comfort and psychological safety. They reclined with eye shades and listened to a curated music playlist for approximately eight hours. Two trained therapists remained in the room for the duration of the experience. Afterward, participants attended three integration sessions to process their experience and incorporate any psychological insights into their daily lives.
To measure changes in suicidal thoughts, the researchers used a clinical interview tool known as the Modified Scale for Suicidal Ideation. They assessed participants before the treatment, and then again at one, three, and twelve weeks after the dosing session. They also used the Montgomery-Asberg Depression Rating Scale to track changes in overall depressive symptoms.
The researchers found large and statistically significant reductions in suicidal thoughts by the primary endpoint at week three. Participants experienced an average drop of almost fourteen points on the suicidal ideation scale. The improvement was rapid, with significant reductions appearing just one week after the dosing session. These benefits were highly durable, maintaining their significance through the final twelve-week assessment.
By the third week, seventy-five percent of the participants met the criteria for a positive anti-suicidal response, meaning their suicidal ideation scores dropped by at least half. Additionally, forty-five percent of the participants achieved full remission of their suicidal thoughts. Depression scores followed a similar trajectory, dropping significantly and remaining low across the entire twelve-week follow-up period.
Aaronson noted that these outcomes exceeded their initial expectations. “We did not expect to see such a high remission rate,” he said. He added that the symptom improvements lasted a long time for many of the individuals involved. “For many of the participants the efficacy was durable for the 12 weeks they were followed post dosing,” Aaronson explained.
Changes in depression severity and suicidal ideation were strongly correlated. However, the initial drop in suicidal thoughts at week one was slightly larger than the drop in overall depressive symptoms. This provides evidence that psilocybin might exert some specific anti-suicidal effects independent of its general antidepressant qualities.
“Suicidal ideation tended to demonstrate a better target for the treatment than depressive symptomatology but it is a more discrete target,” Aaronson told PsyPost.
The safety profile of the intervention was generally favorable. No severe adverse events occurred, and no participants dropped out of the trial. The most common side effects included transient, mild to moderate experiences of nausea, headache, and anxiety. One participant required a standard anti-anxiety medication on the day of the dosing session to manage a panic attack.
Importantly, the findings provided evidence against the idea that the drug inherently worsens suicidal thinking. “There was no significant evidence for a pattern of increased risk of suicidal ideation after a single psychedelic dose of a synthetic psilocybin,” Aaronson explained.
He added that the general outcomes were highly positive for the majority of the group. “Overall, 14 of 20 volunteers demonstrated remission or near remission of their suicidal ideation three months after a single dose of psilocybin,” Aaronson said.
Exploratory analyses revealed some interesting differences between those who responded well to the treatment and those who did not. Participants who did not respond to the psilocybin therapy tended to harbor stronger feelings of hopelessness and pessimism before the trial began. Those who strongly believed that things would never get better appeared less likely to experience an early reduction in suicidal thoughts.
“Participants who had less pessimism and/or hopelessness at baseline and the day after dosing tended to be the remitters,” Aaronson observed. “This suggests that expectancy is a strong force and greater preparation prior to dosing may improve outcomes in the most pessimistic patients.”
The research team also discovered that the screening process might have missed the full severity of some participants’ conditions. “Some of the participants reported they were in fact more suicidal than they said at screening,” Aaronson said. “They were afraid of being excluded. The main concern in a study like this is we were trying to avoid including participants who reported immediate suicidal intent.”
While these findings are promising, they come with some limitations that readers should consider. Aaronson highlighted the preliminary nature of the trial. “This was an open label, small N study and participants were carefully screened and followed,” he said.
An open-label design cannot rule out the placebo effect, and a small N refers to a low number of participants. Participants who volunteer for psychedelic trials often hold strong positive expectations about the treatment, which can heavily influence their subjective outcomes. Without a control group receiving a placebo, it is difficult to determine exactly how much of the improvement stems from the drug itself versus the psychological expectation of healing.
The small sample size of twenty people limits the ability to generalize these results to the broader population. A small group size also makes it difficult to detect rare but potentially serious side effects. The study took place at a single academic center with highly specialized therapists, which might not reflect the care available in standard psychiatric clinics.
Safety concerns also remain a priority, as two participants experienced an increase in their suicidal ideation scores relative to their baseline. For one individual, this worsening was temporary. For another, the elevated suicidal thoughts remained at the end of the twelve-week study.
Aaronson provided context for this specific case. “There was one participant who did finish with a modestly higher level of suicidal ideation at 12 weeks but that person met remission criteria immediately after dosing so we are likely looking at a reaction to losing the psychedelic support rather than the psychedelic causing the increase,” he said.
Another complicating factor involves the resumption of other medications. More than half of the participants restarted standard psychiatric medications after the third week of the study. While the primary benefits were observed before these changes occurred, the reintroduction of outside drugs makes it difficult to attribute the twelve-week durability strictly to the single dose of psilocybin.
This study was funded by Compass Pathways, the pharmaceutical company that developed the synthetic psilocybin formulation used in the trial. The authors noted that the company had no role in designing the study, collecting the data, or interpreting the final results. Several authors reported receiving personal fees, grants, or holding stock options with Compass Pathways and other pharmaceutical companies.
Future research will need to employ larger sample sizes and randomized, placebo-controlled designs to better isolate the specific effects of psilocybin. Scientists hope to conduct longer follow-up periods to understand whether the therapeutic benefits endure beyond three months. They also aim to test if additional dosing sessions or ongoing integration therapy might help consolidate and maintain the positive mental health gains over time.
Aaronson indicated that plans for continued research are already underway. “I am currently looking for funding for a larger study,” he said. He emphasized that helping this specific group of patients remains a priority. “I hope this helps open the door for support for further studies in this often neglected population,” Aaronson concluded.
The study, “Efficacy and Safety of a Single Dose of Psilocybin for Chronic Suicidal Ideation: An Open-Label Trial,” was authored by Andrew van der Vaart, Jeffrey LaPratt, Kimberly Swartz, Audrey Shoultz, Margo Lauterbach, Trisha Suppes, Harold A. Sackeim, and Scott T. Aaronson.
Leave a comment
You must be logged in to post a comment.